Mortality benefits of influenza vaccination in elderly people

The Lancet Infectious Diseases

Volumn 8, Issue 8, 2008, Pages 461-462

  Voordouw, Bettie CG ^a   Sturkenboom, Miriam C ^b   Dieleman, Jeanne P ^b   Stricker, Bruno H ^b,c  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Inspectorate for Health Care ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

CLINICAL TRIAL; DRUG EFFECT; ELDERLY CARE; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; LETTER; MORTALITY; NETHERLANDS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 47349129457     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70162-2     Document Type: Letter

References (3)

1. Simonsen L., Taylor R., Viboud C., Miller M., and Jackson L. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 7 (2007) 658-666
2. Voordouw A., Sturkenboom M., Dieleman J., et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 292 (2004) 2089-2095
3. Govaert T., Thijs C., Masurel N., Sprenger M., Dinant G., and Knottnerus J. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272 (1994) 1661-1665